Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children’s Oncology Group. Cancer

Oberoi S, Qumseya A, Xue W, Venkatramani R, Weiss AR. Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children’s Oncology Group. Cancer. 2024 Jul 15;130(14):2493-2502. doi: 10.1002/cncr.35276. Epub 2024 Mar 12. PubMed PMID: 38470405; PubMed Central PMCID: PMC11214599.

We aimed to estimate event-free survival (EFS) of children and young adults with relapsed or refractory NRSTS treated in non-randomized phase II studies conducted by Children’s Oncology Group (COG) and predecessor groups to establish a benchmark EFS for future phase II NRSTS trials evaluating the activity of novel agents. A retrospective analysis of recurrent or refractory NRSTS patients prospectively enrolled in non-randomized phase II COG and predecessor group trials between 1994 and 2015 was conducted. The EFS was defined as disease progression/relapse or death and calculated using the Kaplan-Meier Method. The Log-rank test and relative-risk regression were used to compare EFS distribution by age at enrollment, sex, race, NRSTS histology, prior lines of therapy, calendar year of trial and type of radiographic response.